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The utility of the venous clinical severity score in
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Objectives: The goal of endovenous ablation is to reduce the symptoms associated with chronic venous insufficiency. This
prospective study was designed to apply the venous clinical severity score to limbs before and after endovenous saphenous
vein radiofrequency ablation and to identify risk factors associated with treatment failure.
Methods:Between September 2003 andMarch 2005, 499 patients underwent 682 saphenous vein radiofrequency ablation
procedures. Preoperative venous clinical severity scores were documented. Follow-up clinical and duplex examinations
were performed at 4 days, 4 weeks, and 4 months after saphenous vein radiofrequency ablation and at >6 months
thereafter. Venous clinical severity scoring was repeated at follow-up visits, and patients were asked to evaluate their level
of satisfaction with the procedure.
Results: The mean  standard deviation age of the patients was 53.5  13.3 years (range, 28 to 86 years), and 68% were
women. Pretreatment CEAP clinical class C3/C4 comprised 80% of limbs (520/682). Preoperative, 4-day, 4-week, and
4-month venous clinical severity scores were, respectively, 8.8 3.7 in 648 limbs, 5.2 3.0 in 629, 4.1 2.4 in 530, and
3.3  1.6 in 479 limbs. Saphenous vein radiofrequency ablation significantly reduced pain related to lower extremity
venous disease from 95.7% to 15.2% (P< .0001) and edema from 92.4% to 17.0% (P< .0001). Before treatment, venous
stasis ulcers were present in 52 limbs and healed at a rate of 86%. Complications in 633 limbs at last follow-up included
superficial thrombophlebitis in 12.0%, paresthesia in 0.3%, and nonocclusive thrombus extension in 0.2%. No skin
thermal injury was observed. Fewer than 2% of patients reported dissatisfaction with their procedural outcome. Age
(relative risk, 0.98; P  .06), female sex (relative risk, 0.19; P < .0001), and tumescent volume >250 mL (relative risk,
0.59; P  .06) were associated with higher rates of occlusion. The overall occlusion rate was 87.1%.
Conclusions: As determined by the venous clinical severity score, treatment of saphenous vein reflux with endovenous
radiofrequency ablation results in the clinical improvement of symptoms and aids in the healing of venous ulcers. Age,
female sex, and tumescent volume are associated with high success rates of occlusion.We found the venous clinical severity
score to be an excellent stand-alone tool for assessing outcomes after saphenous vein radiofrequency ablation. (J Vasc
Surg 2007;45:1008-15.)Outcome assessment is a term of growing importance in
vascular surgery. Properly formatted and validated out-
come assessment tools are valuable. The venous severity
score (VSS) was proposed by the Ad Hoc Committee on
Venous Outcomes Assessment of the American Venous
Forum in March 20001 to assess the usefulness of an
intervention in patients with chronic venous insufficiency
(CVI). The validity of the VSS was later evaluated and was
confirmed by different groups2,3 and was found to be
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1008reliable when tested against abnormalities seen on ultra-
sonography.4 Various endovenous ablative treatments for
CVI have resulted in a dramatic change in the way such
patients are treated.5-9
The VSS is composed of the following three elements
that are closely aligned with the CEAP (clinical grade,
etiology, anatomy, and pathophysiology) clinical class:
● the venous clinical severity score (VCSS): a modifica-
tion to replace the clinical score of CEAP;
● the venous segmental disease score (VSDS): a combi-
nation of the anatomic and pathophysiologic compo-
nents of CEAP, and
● the venous disability score (VDS): a modification of
the original CEAP disability score).1
The CEAP classification system and its recent revi-
sion10,11 are primarily descriptive tools used to classify and
categorize patients on presentation. The CEAP classification
is relatively static, however, changing little over time and is a
poor method to assess the usefulness of an intervention.
The VSS is first and foremost an evaluative instrument.
It was designed not to replace CEAP but to supplement it
and provide a method for serial assessment. It is proven to
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basic components of the system are easy to learn and apply. It
is critically needed for the longitudinal follow-up of a patient’s
clinical condition during and after an intervention.2
Despite its proven value and acceptance, the VSS is an
underused outcome assessment tool. This study was con-
ceived with the notion that the VCSS component of VSS
can be used as a stand-alone scoring system2 by the prac-
ticing surgeon with little effort. We found the addition of
the VSDS or VDS to be impractical in our daily practice.
The objectives of this study were to assess the outcome of a
large cohort of patients undergoing endovenous saphenous
vein radiofrequency ablation (RFA) using the VCSS and to
identify risk factors associated with treatment failure.
METHODS
All consecutive patients who underwent RFA between
September 2003 and March 2005 for varying degrees of
symptomatic CVI in a private office by a single surgeon
(M. A. V.) were prospectively entered into a database.
Preoperative CEAP clinical class (Fig 1; Table I, online
only) and full VCSSs (Fig 1; Table II) were documented
during an office-based examination by one of three exam-
iners. All patients underwent color flow duplex ultrasound
examination with a high-resolution linear probe (7 to 12
MHz) using the Acuson Aspen (Siemens Medical Solu-
tions, Erlangen, Germany). They all had documented sa-
phenofemoral or saphenopopliteal reflux. Reflux was de-
fined as reverse flow in the saphenous vein 0.5 seconds
after calf compression or when placed in the standing
position. All anatomic locations of reflux were recorded.
The RFA treatment was offered only to patients who
had persistent symptomatic venous disease CEAP clinical
class II through VI, including persistent pain, swelling,
itching, heaviness, achiness, fatigue or complications,
hemorrhage, phlebitis, skin changes, or venous ulcer-
ation (Fig 1). These patients were unresponsive to conser-
vative treatment measures, including leg elevation, weight
loss in appropriate patients, and the use of graduated com-
pression stockings (20 to 40 mm Hg) for at 3 months.
Patients with venous ulcers, recurrent phlebitis, or bleeding
varices did not require a trial of conservative measures
before being offered surgical treatment.
Patients were excluded on the basis of recent deep vein
thrombosis (DVT), venous outflow obstruction, arterial
insufficiency with an ankle-brachial index 0.8, planned
future pregnancy, noncompliance with conservative mea-
sures, or severe obesity making visualization of the saphe-
nofemoral junction with ultrasound imaging difficult.
Patients were not excluded on the basis of having a post-
thrombotic state or concomitant deep or perforator reflux.
No adjunctive treatments (ie, sclerotherapy, micro-
phlebectomy, perforator ablation) were performed for ap-
proximately 6 months after RFA.
All RFA procedures were performed with tumescent
local anesthesia and intravenous sedation. The Closure
procedure (VNUS Medical Technologies, San Jose, Calif)
was used for RFA. Patients’ refluxing great saphenous veins(GSVs), short saphenous veins (SSVs), and accessory sa-
phenous veins (SVs; anterior SV and posterior SV) were
mapped before surgery. Most GSVs were accessed per-
cutaneously near the knee. The size of the catheter (6F
or 8F) was determined by the greatest diameter of the
GSV (6F for 0.8 cm and 8F for 0.8 cm). Most SSVs
were accessed in the mid to lower calf. Most anterior SVs
were accessed in the mid anterolateral thigh. Refluxing
GSVs, SSVs, and accessory SVs were treated, especially
when found to be feeding symptomatic clusters. Occa-
sionally, 150-cm hydrophilic-coated wires were used for
vein segments that were difficult to traverse.
Ultrasound (SonoSite Titan, Bothell, WA) guidance
was used to verify the position between 0.5 and 1.0 cm
from the saphenofemoral junction (or saphenopopliteal
junction for SSV) near the orifice of the superficial epigas-
tric vein. Intraoperative ultrasound was then used to guide
delivery of tumescent anesthesia (0.1% lidocaine with epi-
nephrine). This was infiltrated generously along the course
of the vein underneath the perivenous fascia throughout
the entire length of the vein, creating a good halo effect and
good compression of the vein throughout its length. The
vein was positioned with the tumescent anesthesia well
below the skin (1 cm). Trendelenburg positional exsan-
Fig 1. A, CEAP classification at the time of screening. B, venous
clinical severity score (VCSS) at screening.guination also was used.
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vein was heated to 85° 5°C. The pullback proceeded at a
rate of 1 cm/min for the first 3 minutes and then increased
to 2 to 3 cm/min for the remainder of the treatment.
Intraoperative duplex ultrasound imaging was used to as-
sess the adequacy of the occlusion. Patent veins were im-
mediately retreated until closed.
All legs were wrapped with elastic bandages and self-
adhering wrap (Coban, 3M, St. Paul, Minn), which were
removed the next day. Patients were sent home that day and
were allowed to engage in all usual activities, except heavy
exercise for 2 weeks. Instructions were given for compression
to be used indefinitely12 but especially for the first several
months. Prophylaxis for deep vein thrombosis was not used.
Follow-up clinical and duplex ultrasound examinations
were performed at 4 days, 4 weeks, and 4months after RFA
and at 6 or more months thereafter. All components of the
VCSS were individually evaluated for assessing the contri-
bution of each component over time. At follow-up visits,
limbs were rescored and patients were asked to evaluate
their level of satisfaction with the procedure (very satisfied,
partially satisfied, or not satisfied). Complications such as
superficial thrombophlebitis, infection, paresthesia, signifi-
cant ecchymosis, or skin burns were identified. At later
periods, a small percentage of patients (10%) who were
unable or unwilling to come in were contacted by tele-
phone to determine their VCSS and their level of satisfac-
tion. All ulcers were followed up until healed. Most ulcer
care consisted of a multilayered compression dressing.
Statistical analysis. Data were analyzed using SAS 9.1
software (SAS Institute, Cary, NC). Comparison of treat-
ment effect on variables related to the VCSS was analyzed
by 2 statistics.Wilcoxon statistics were used to evaluate the
treatment effect on the VCSS owing to the non-normal
distribution of the VCSS. Generalized mixed-effects mod-
els13,14 were used to evaluate the effects of treatments and
time since surgery on occlusion rate. Occlusion was consid-
ered as a repeated event and measurement in the model
because some limbs underwent repeat RFA for a first treat-
ment failure. The model also adjusted for within-subject cor-
relation between the left and right limbs by using subject and
limb as random effects. The independent variables that were
evaluated included age, sex, baseline VCSS, time since sur-
gery, size of catheter used (6F or 8F), length in centimeters of
SV treated, and volume in milliliters of tumescence. Contin-
uous data are presented as means standard deviation.
RESULTS
The study included 499 patients (68% female) with 682
limbs (52% left). The mean age was 53.5  13.3 years
(range, 28 to 86 years). There were 47 limbs in C2 class,
417 limbs in C3, 104 limbs in C4, 31 limbs in C5, and 49
limbs in C6. Pretreatment CEAP clinical class C3/C4
comprised 80% of limbs (523/682; Fig 1). The mean
pullback length was 29  4 cm, and the mean amount of
tumescent anesthesia used was 247 10mL. The GSVwas
the only treated vein in 83% of limbs, whereas the anterior
accessory SV and SSV were treated in 14% and 3% of limbs,respectively. The overall patient satisfaction (partly or very
satisfied) at the last follow-up was 98.4%.
Treatment effects on the venous clinical severity
score–related signs or symptoms. The effects of treatment
Table III. Longitudinal venous clinical severity score
component change
Variable*
Initial
screening†
(n  648)
Last follow-up†
(n  631)
Pain
None 28 (4.3) 535 (84.8)
Occasional 202 (31.2) 79 (12.5)
Daily 361 (55.7) 14 (2.2)
Daily with medications 57 (8.8) 3 (0.5)
Varicose veins
None 8 (1.2) 208 (33.0)
Few 116 (17.9) 381 (60.4)
Multiple 409 (63.1) 40 (6.3)
Extensive 115 (17.7) 2 (0.3)
Venous edema
None 50 (7.7) 524 (83.0)
Evening only 215 (33.2) 92 (14.6)
Afternoon 290 (44.8) 12 (1.9)
Morning 93 (14.4) 3 (0.5)
Skin pigmentation
None 449 (69.3) 501 (79.4)
Limited, old 100 (15.4) 96 (15.2)
Diffuse, recent 75 (11.6) 27 (4.3)
Wider, recent 24 (3.7) 7 (1.1)
Inflammation
None 582 (89.8) 619 (98.1)
Mild cellulitis 49 (7.6) 12 (1.9)
Moderate cellulitis 15 (2.3) 0
Severe 2 (0.3) 0
Induration
None 538 (83.0) 587 (93.0)
Focal 5 cm 40 (6.2) 30 (4.8)
Medial leg 58 (9.0) 10 (1.6)
Diffuse leg 12 (1.9) 4 (0.6)
Active ulcers (n)
0 596 (92.0) 624 (98.9)
1 35 (5.4) 5 (0.8)
2 14 (2.2) 2 (0.3)
2 3 (0.5) 0
Ulcer duration (months)
0 596 (92.0) 624 (98.9)
3 13 (2.0) 2 (0.3)
3-12 33 (5.1) 3 (0.5)
12 6 (0.9) 2 (0.3)
Active ulcer size (cm)
0 596 (92.0) 624 (98.9)
2 23 (3.5) 5 (0.8)
2-6 23 (3.5) 1 (0.2)
6 6 (0.9) 1 (0.2)
Compression therapy
None 7 (1.1) 39 (6.2)
Intermittent 37 (5.7) 68 (10.8)
Most days 439 (67.7) 360 (57.1)
Fully comply 165 (25.5) 164 (26.0)
VCSS mean score 8.8 3.6
VCSS, Venous clinical severity score.
*P  .0001 for all variables.
†Data are given as number (percentage).on the VCSS components are summarized in Table III and
score
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pain (95.7% to 15.2%, P  .0001), the percentage of limbs
with multiple or extensive varicosities (80.8% to 6.6%, P 
.0001), venous edema (92.4% to 17.0%, P  .0001), skin
pigmentation (15.3% to 5.4%, P .0001), cellulitis (10.2% to
1.9%, P  .0001), and induration (17.1% to 7.0%, P 
.0001).
RFA also significantly encouraged ulcer healing. The
number of limbs with one, two, and more than two active
ulcers were 35 (5.4%), 14 (2.2%), and three (0.5%) before
RFA and five (0.8%), two (0.3%), and zero after RFA,
respectively (P  .0001). The number of limbs with lower
extremity ulcers for 3 months, 3 to 12 months, and 12
months were 13 (2.0%), 33 (5.1%), and six (0.9%) before
RFA and two (0.3%), three (0.5%), and two (0.3%) after
RFA, respectively (P  .0001). The number of limbs with
ulcer sizes2 cm, 2 to 6 cm, and6 cmwere 23 (3.5%), 23
(3.5%), and six (0.9%) before RFA and five (0.8%), one
(0.2%), and one (0.2%) after RFA, respectively (P 
.0001). The overall rate of ulcer healing was 86%.
The distribution of the number of limbs using com-
pression therapy was significantly different before and after
RFA. The number of limbs in which compression therapy
was intermittently used, used most days, and fully complied
with was 7 (1.1%), 37 (5.7%), 439 (67.7%), and 165
(25.5%) before RFA and 39 (6.2%), 68 (10.8%), 360
(57.1%), and 164 (26.0%) after RFA, respectively (P 
.0001).
Preoperative, 4-day, 4-week, and 4-month venous clin-
ical severity scores were 8.8  3.7 in 648 limbs, 5.2  3.0
in 629, 4.1  2.4 in 530, and 3.3  1.6 in 479, respec-
tively. Limbs in which the vein remained occluded had a
mean baseline score of 8.84, and a last follow-up score of
3.60. Limbs with veins that failed to occlude had a mean
baseline score of 8.70 and last follow-up score of 3.85. The
overall mean VCSS was 8.8 at baseline and 3.6 at last
Fig 2. Venous clinical severityfollow-up (P  .0001).Complications associated with therapy. RFA ther-
apy resulted in 160 patients experiencing 184 complica-
tions. Complications that developed after RFA in the 633
limbs included ecchymosis in 83 (13.1%), thrombophlebi-
tis in 76 (12.0%), erythema in 16 (2.5%), hyperpigmenta-
tion in 4 (0.6%), infection in 3 (0.5%), and paresthesia in
2 (0.3%). None of the complications were permanent. No
thermal skin injury was observed. One patient had a non-
occlusive asymptomatic deep vein thrombosis (DVT) dis-
covered on routine initial postoperative duplex ultrasound
imaging.
Factors affecting occlusion rate. Our overall occlu-
sion rate was 87.1%. Table IV gives the variables associated
with the failure of venous occlusion. Each year of age
increment is associated with a 2% risk reduction of occlu-
sion failure. The relative risk (RR) of patient age in associ-
ation with the patency of the treated vein was 0.98 (95%
confidence interval [CI], 0.96 to 1.00; P  .06). Women
were 81% less likely to experience occlusion failure than
men (RR, 0.19; 95% CI, 0.09 to 0.41; P  .0001).
Limbs treated with 6F catheters had a 26% lower risk of
occlusion failure than those treated with 8F catheters
(RR, 0.74; 95% CI, 0.43 to 1.28; P  .28). Each 1-cm
length increment of treated SV was associated with a 3%
risk increment in vein recanalization (RR, 1.03; 95% CI,
Table IV. Factors associated with treatment failure
Factor RR (95% CI) P
Age 0.98 (0.96-1.00) .06
Female sex 0.19 (0.09-0.41) .0001
Catheter size, 6F vs 8F 0.74 (0.43-1.28) .28
GSV side, right vs left 1.03 (0.98-1.09) .19
Tumescent volume 0.59 (0.34-1.02) .06
RR, Relative risk; CI, confidence interval; GSV, great saphenous vein.
(VCSS) components over time.0.98 to 1.09; P  .19). Limbs receiving 250 mL of
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tion than those that received less (RR, 0.59; 95% CI,
0.34 to 1.02; P  .06). Limbs overall had a mean VCSS
decrease whether they remained occluded (5.3  3.3) or
whether they recanalized (4.9  2.8) that was not found
to be statistically significant (P  .16).
DISCUSSION
Although clinical occlusion rates, durability, quality-of-
life, and patient satisfaction with endovenous RFA have
been reported.5,6,8,9 few data exist on outcome assessment
using an existing reliable, reproducible, and validated tool
such as VCSS in a substantial patient population. We be-
lieve that documenting the VCSS by itself on initial and
subsequent visits is an easy and effective way to monitor
clinical progress or regression, independent of CEAP clas-
sification or ultrasound findings.
The importance of evaluating each of the components
of the VCSS cannot be overemphasized. We disagree with
the suggestion by Kakkos et al3 that “further modifications
in VCSS might increase its sensitivity in monitoring out-
come of venous surgery.” Although some components of
the VCSS do not change after surgery as much as others, we
found statistically significant improvement for each compo-
nent of the VCSS after RFA. The strength of the VCSS lies
in its evaluative properties identifying subtle intrasubject
changes after an intervention over time. Teasing out these
componential differences has proven valuable in several ways:
1. It has allowed us to identify technical factors that may
contribute to better outcomes.
2. It has helped us to know what to expect after the
intervention and to relay those expectations to patients.
3. It provides a method to compare, in a structured format,
different types of SV ablative techniques.
The most dramatic symptom improvement was ob-
served at 1month (Fig 2), with significant reduction in pain
and swelling. Correspondingly, we found a significant se-
quential drop in the VCSS over each time interval (preop-
erative, 4 days, 4 weeks, and 4 months) to 8.8 3.7, 5.2
3.0, 4.1 2.4, and 3.3 1.6, respectively (Fig 3). This was
not reliably accompanied by disappearance of varicose veins.
There is ongoing debate about the timing of adjunctive
procedures.15,16 We found that most limbs did not require
microphlebectomy or sclerotherapy after RFA for smaller
varices. Larger residual varices diminished most in size
during the first 4 months after ablation, but less so there-
after (Fig 2). Therefore, we do not perform routine micro-
phlebectomy at RFA, but rather wait at least 4 months for
reassessment to determine the necessity.
We found that the most important technical factor
associated with successful occlusion was the amount of
tumescent anesthesia used. Tumescence extrudes blood
from the vein, narrows the vein diameter during treatment,
and protects surrounding tissues from the radiofrequency
energy. Our mean length of pullback was 29  5 cm, and
our mean volume of tumescence was 247  10 mL. Our
occlusion rate improved as the volume increased, ap-proaching statistical significance at 250 mL. We there-
fore recommend using at least 10 mL of tumescence per
1-cm segment treated. Infiltration of fluid just beyond
and around the tip of the catheter near the saphenofemo-
ral junction to better compress it as it splays is of primary
importance (Fig 4).
There was no statistically significant difference in recur-
rence associated with the catheter size, although veins
treated with the 6F catheter tended to stay closed longer.
Fig 3. A, Before and (B) after tumescent compression at the
saphenofemoral junction. Arrows point to tumescent fluid.
Fig 4. Mean venous clinical severity score (VCSS) throughout
the study.We expected to find a higher rate of recurrence with larger
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cence with larger-diameter veins. We also found it safe to
treat large-caliber veins with RFA without concomitant
high ligation.5
Our occlusion failure rate is comparable to that de-
scribed by others for RFA.5,7,9 Our observations were
similar to previous reports that anatomic occlusion failures
did not necessarily result in symptom regression, physio-
logic reflux, or patient dissatisfaction.5,7,9 Our findings
supported this observation with no significant differences in
the VCSS between limbs with treated segments that re-
mained occluded and those that recanalized. The reason for
this is not entirely clear. It may be related to segmental
partial occlusions or to luminal narrowing. Male sex and
younger age were associated with significantly higher rates
of occlusion failure. Some have speculated that differences
in collagen structure or inflammatory response in the vein
wall may offer an explanation, but this is not proven.5
The relevance of increasing occlusion failure per centi-
meter of increased pullback length is in question, with weak
statistical significance. Nevertheless, in our experience,
treatment at a suitable point by ultrasound imaging near
the knee is satisfactory for most limbs to achieve a reduction
in the VCSS with few resultant paresthesias. There are
anatomic reasons why this is satisfactory.17 Proximal to the
posterior arch vein-GSV junction, perforators do not typi-
cally communicate with the GSV. Ablation to this point
eliminates most of the hydrostatic forces of superficial vein
reflux.18
A few limbs with swelling, ulceration, or persistent
unchanged symptomatic varicosities have required retreat-
ment from the previously occluded low thigh to the mid
calf after the study period. In most of these limbs, a large
Boyd perforator, an accessory meandering vein, or a more
recently described “popliteal fossa vein”19 reconnected
with the GSV at this point, causing the problem. We have
since adapted our preoperative mappings to look for these
to preemptively treat.
Our mean VCSS is higher than that obtained by
others2,3,20,21 and is reflected in the higher CEAP classes
(Fig 1). We believe the power of the study is derived from
these higher scores and CEAP classes. Others have sug-
gested that higher scores offer more sensitivity and may be
more appropriate to monitor therapy.2,20 Baseline values
were obtained in the week before the procedure, which
explains the high compression compliance. An overall drop
occurred in the VCSS at each time interval, with a starting
mean score of 8.8 and an ending mean score of 3.3 at 4
months. The last follow-up mean score of 3.6 is higher
because it reflects the scores of all limbs, regardless of the
time of drop out, and is statistically significant (P .0001).
Those limbs that were followed up at 1 year had a mean
score of 2.7 (Fig 3). Symptomatic limbs simply respond
better. Nevertheless, the VCSS maintains its validity even
with higher limb scores.2
The VCSS drops significantly when an ulcer heals. Our
highest VCSS was 26, which dropped to 9 at the 1-year
follow-up. Ablation of superficial reflux combined withcompression and wound care compliance contributed to
the high rate of ulcer healing by elimination of hydrostatic
forces. We are not in agreement with others18 on the
algorithm to follow in the treatment of limbs with leg
ulcers. We prefer RFA as the initial step because it is simple
to perform, with little morbidity. Recalcitrant or recurrent
ulcers are related to untreated hydrodynamic forces and
may require adjunctive treatments.18,21 Longer follow-up
is needed to determine the overall reduction in the rate of
ulcer recurrence.12We also learned that compression needs to
remain amainstay of treatment for CVI with or without RFA.
We found the VCSS portion of VSS to be not only the
most practical but also the more reasonable instrument to
use for outcome analysis purposes. Using the VCSS alone is
like using the clinical portion of CEAP, but with an ex-
panded scale and the flexibility of changing in response to
treatment. The VSDS combines the pathophysiologic
mechanisms (reflux and obstruction) with the anatomic
distribution of the diseased veins, and in this cohort with
predominantly superficial venous reflux, there was little
relevance. The VSDS has been deemed “arbitrary”1 and
“especially hard to score and interpret”20 and is not prac-
tical for a longitudinal study. In addition, an occlusion
failure would have negatively affected the VSDS but does
not reliably affect the VCSS.
With respect to the VDS, the scoring system has been
found to be simple to use20; however, it has little applica-
bility when two limbs of an individual are involved. In our
study, 183 patients had both limbs treated. Last, the VCSS
has been found to be valid and reliable on its own merits,
with high interobserver and intraobserver agreement.2 We
subscribe tenaciously to the premise that the VCSS can
stand alone for outcome assessment.
We encountered only one DVT (0.2%) in this series
(Table V), which resolved after warfarin therapy. This
patient had postphlebitic syndrome and was taking long-
term warfarin for a previous pulmonary embolism. He had
disabling pain from ulceration, with a VCSS of 22 at
screening and 6 at the last follow-up. Additional complica-
tions were paresthesia in two limbs (0.3%), hyperpigmen-
tation in four (0.6%), and ecchymosis in 83 (13.1%). Su-
perficial phlebitis occurred in 76 limbs (12.0%) and is most
frequently found in limbs with large varicosities. This is
Table V. Complications with therapy among 633
patients at last follow-up
Complication N (%)
Hyperpigmentation 4 (0.6)
Superficial phlebitis 76 (12.0)
Paresthesia 2 (0.3)
Erythema 16 (2.5)
Ecchymosis 83 (13.2)
Infection 3 (0.5)
Thermal injury 0
Deep venous thrombosis 1 (0.2)likely related to relative stagnation in flow in these tributar-
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porarily, and resolved without further therapy.
Drawbacks to the study include the fact that although
three individuals in the same office performed the VCSS
documentation, one individual performed all the proce-
dures. As a corollary, bias may be introduced into scoring as
familiarity with a patient grows even though the same
standardized form was used. In addition, scores may fluc-
tuate significantly during the longer intervals between
snapshots. A substantial number of random patients were
lost to follow-up after 6 months, necessitating the time of
last follow-up as an end-point measure. Also, telephone
contact for scoring was used for those patients who were
unable or unwilling to come to the office. At the time, all
procedures were performed in the operating room under
sedation, and now most procedures are performed with
local anesthesia in an office setting.
CONCLUSION
Evidence-based medicine and outcome assessment are
critical tools for vascular surgery. The results of high-
volume procedures should be followed up with a validated
instrument. We found the VCSS and each of its compo-
nents to be useful, significant, and easily applicable for the
assessment of outcomes after RFA in limbs with symptom-
atic venous insufficiency. Increasing age and female sex are
independent predictors of higher rates of occlusion. Vol-
ume of tumescence per treatment length is the most impor-
tant technical factor for occlusion. Treatment to the knee is
sufficient for most limbs, with few adverse events. Ana-
tomic failure does not necessarily predict a rise in the VCSS.
A waiting period of 4 months should be endured before the
adjunctive treatment of residual varicosities.
The VCSS, by itself, is an important evaluative instru-
ment in the treatment of CVI. Using VCSS alone is com-
parable to the common usage of the clinical portion of
CEAP. The VCSS should be used for outcome assessment
in any study comparing different treatment modalities for
SV ablation.
Special thanks is given to Merrill Dayton MD, Chair-
man and Professor of Surgery SUNY Buffalo for his exhor-
tation to a private surgeon to follow his results.
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Dr Nicholas J. Morrissey (New York, NY). Thank you very
much for the opportunity to discuss the paper. I really just have one
question. You correlated the French size of the catheter a little bit
in terms of the results of failure. Could you correlate that, and did
you correlate that, with the size, the diameter of the vein, which I
think is probably the most strong predictor of failure using this
technology. And that’s the only question I have and thank you.
Dr Michael Vasquez. We mapped and measured all veins
beforehand, but we did not directly correlate that with the data.
Although it wasn’t statistically significant, we did notice that
people in which we had to use the 8 French catheter—which had
larger vein diameters in general—had a slightly higher rate of
recanalization than those patients in which we only used a 6 French
catheter. We treated many very large veins; however, we did not
correlate vein diameter with the data, and it is something that I
would like to do at some point. We concentrated mostly on thescoring system. The study was about the scoring system more than
it was about factors for treatment failure.
Dr Robert B. Rutherford (Corpus Christi, Tex). Just a short
comment about venous severity scoring in relation to this paper
which supports its use in association with superficial vein surgery.
Other who have tried to use this score in this setting, particularly
the French phlebologists, have reported that it doesn’t really help
much in superficial venous disease, in patients with low CEAP
scores. I think the difference in its utility here lies in your patient
population, who mostly had symptomatic varicose veins with
higher CEAP scores. Those other studies reflected more of the
cosmetic end of varicose vein spectrum, patients with lower CEAP
and venous severity scores. I think if you have patients with
significant symptoms, the score will work even for superficial
venous surgery. I really appreciate your paper. Thank you.Dr Vasquez. Thank you.
6 Skin changes in conjunction with active ulceration
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May 20071015.e1 Vasquez et alTable I (online only). CEAP clinical class
Class Description
0 No visible or palpable signs of venous disease
1 Telangiectases, reticular veins, malleolar flare
2 Varicose veins
3 Edema
4 Skin changes ascribed to venous disease
5 Skin changes in conjunction with healed ulceration
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 5 Vasquez et al 1015.e2Table II (online only). Venous clinical severity score*
Attribute Absent  0 Mild  1 Moderate  2 Severe  3
Pain None Occasional, not restricting
activity or requiring
analgesics
Daily, moderate activity
limitation, occasional
analgesics
Daily, severe, limiting activities
or requiring regular use of
analgesics
Varicose veins† None Few, scattered; branch
varicose veins
Multiple: GSV varicose
veins confined to calf or
thigh
Extensive: Thigh and calf or
GSV and lesser saphenous
vein distribution
Venous edema‡ None Evening ankle edema only Afternoon edema, above
ankle
Morning edema above ankle
and requiring activity
change, elevation
Skin
pigmentation§
None or focal, low
intensity (tan)
Diffuse but limited in area,
and old (brown)
Diffuse over most of
gaiter distribution
(lower 1/3) or recent
pigmentation (purple)
Wider distribution (above
lower 1/3) and recent
pigmentation
Inflammation None Mild cellulitis, limited to
marginal area around ulcer
Moderate cellulitis,
involving most of gaiter
area (lower 1/3)
Severe cellulitis (lower 1/3
and above) or significant
venous eczema
Induration None Focal, circummalleolar
(5 cm)
Medial or lateral, less than
lower 1/3 of leg
Entire lower 1/3 of leg or
more
Active ulcers (n) 0 1 2 2
Active ulceration,
duration
None 3 mo 3 mo, 1 y Not healed 1 y
Active ulcer, size None 2 cm diameter 2-6 cm diameter 6 cm diameter
Compressive
therapy¶
Not used or not
compliant
Intermittent use of stockings Use of elastic stockings
most days
Full compliance: stockings plus
elevation
GSV, Great saphenous vein.
*Reprinted with permission from Rutherford RB, Padberg FT Jr, Comerota AJ, Kistner RL, Meissner MH, Moneta GL; American Venous Forum’s Ad Hoc
Committee on Venous Outcomes Assessment. Venous severity scoring: an adjunct to venous outcome assessment. J Vasc Surg 2000;31:1307-1312.
†“Varicose” veins must be 4 mm in diameter to qualify, so that differentiation is ensured between C1 and C2 venous disease.
‡Presumes venous origin by characteristics (eg, brawny [not pitting or spongy] edema), with significant effect of standing or limb elevation or other clinical
evidence of venous cause (ie, varicose veins or history of deep venous thrombosis). Edema must be a regular finding (eg, daily occurrence). Occasional or mild
edema does not qualify.
§Focal pigmentation over varicose veins does not qualify.
Largest diameter of largest ulcer.
¶Sliding scale to adjust for background differences in the use of compressive therapy.
